People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vedanta Biosciences, Inc. | — | Biotech / Pharma | Series D+ | $240.3M | $2.0B | 2023 |
| Elion Therapeutics, Inc. | — | Biotechnology | Series B | $25.4M | $185.8M | 2024 |
| ArmaGen, Inc. | — | Biotechnology | Series A | $18.5M | $361.5M | 2018 |
| Tilos Therapeutics, Inc. | — | Biotechnology | Seed | $3.8M | $135.4M | 2016 |
| Abexxa Biologics, Inc. | — | Biotechnology | Seed | $1.2M | $55.5M | 2016 |
| Sentien Biotechnologies, Inc. | — | Biotechnology | Seed | $1.0M | $46.6M | 2015 |
Martin Heidecker at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin Heidecker on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Miller | 1 | 14 |
| Jonathan Leff | 1 | 11 |
| John Edwards | 1 | 8 |
| Curt LaBelle | 1 | 7 |
| Roger Kitterman | 1 | 5 |
| Greg Bailey | 1 | 5 |
| Julius Knowles | 1 | 5 |
| Jim Flynn | 1 | 4 |
| NEIL TIWARI | 1 | 4 |
| Troy Ignelzi | 1 | 3 |
| Bharatt Chowrira | 1 | 3 |
| Jayson Punwani | 1 | 3 |
| Christopher Viehbacher | 1 | 2 |
| Martin J. Heidecker | 1 | 2 |
| Kieren Marr | 1 | 2 |
| John LaMattina | 1 | 2 |
| Arthur J. Tzianabos | 1 | 2 |
| Rich Ganz | 1 | 2 |
| Bennett Shapiro | 1 | 2 |
| Debra Weidanz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.